Press Release

Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia

SAN DIEGO – March 16, 2017Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced preclinical and clinical data will be presented at the 2017 Keystone Symposia on Molecular and Cellular Biology: Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7), to be held March 19-23 in Whistler, British Columbia.

Details of the poster presentation are as follows:

Title: Preclinical and Clinical Data Support Anti-tumor Cellular Immune Response Elicited by Toca 511 and Toca FC Therapy
Poster Number: 4036
Presenter: Derek Ostertag, Ph.D., director, R&D diagnostics at Tocagen
Date and Time: Thursday, March 23, noon PT

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. The company is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information, visit or follow @Tocagen.


Media Contact:
Monica May
Canale Communications
(619) 849-5383